Literature DB >> 24922649

Spontaneous in vitro senescence of glioma cells confirmed by an antibody against IDH1R132H.

Ewelina Stoczynska-Fidelus1, Waldemar Och2, Piotr Rieske3, Michal Bienkowski4, Mateusz Banaszczyk3, Marta Winiecka-Klimek3, Jolanta Zieba3, Karolina Janik3, Kamila Rosiak3, Cezary Treda3, Robert Stawski5, Anna Radomiak-Zaluska6, Sylwester Piaskowski3.   

Abstract

BACKGROUND: We have recently suggested that glioblastoma cells become spontaneously senescent in cell culture conditions. The antibody specific against IDH1(R132H) offers the perfect opportunity to verify this hypothesis.
MATERIALS AND METHODS: We analyzed the features of senescence in 8 glioma cell cultures showing the IDH1(R132H) mutation based on combination of immunocytochemistry, enzymo-cytochemistry, BrdU incorporation assay and real-time microscopic observation.
RESULTS: We report that glioma cells showing the IDH1(R132H) mutation become rapidly and spontaneously senescent in vitro. Senescence was observed in both classical and novel serum-free cell culture conditions. Importantly, the senescent IDH1(R132H)-positive cells showed the expression of stemness marker (SOX2).
CONCLUSION: In vitro senescence appeared to be the main reason of the difficulties in any kind culturing of glioma cells. 3D cell cultures prolonged the survival and in vitro proliferation of neoplastic IDH1(R132H)-positive cells, however, did not enhance the stabilization efficiency. Senescence of glioma cells is spontaneously triggered in vitro, which offers the opportunity of potential new therapeutic strategies based on this phenomenon. Copyright
© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  3D cell culture; IDH1 gene; astrocytoma; glioblastoma; glioma; senescence

Mesh:

Substances:

Year:  2014        PMID: 24922649

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

1.  Different mutational characteristics of TSG in cell lines and surgical specimens.

Authors:  Ewelina Stoczynska-Fidelus; Michal Bienkowski; Marcin Pacholczyk; Marta Winiecka-Klimek; Mateusz Banaszczyk; Jolanta Zieba; Grzegorz Bieniek; Sylwester Piaskowski; Piotr Rieske
Journal:  Tumour Biol       Date:  2014-08-14

Review 2.  Molecular Mechanisms Governing the Stem Cell's Fate in Brain Cancer: Factors of Stemness and Quiescence.

Authors:  Valeriia Gulaia; Vadim Kumeiko; Nikita Shved; Eduardas Cicinskas; Stanislav Rybtsov; Alexey Ruzov; Alexander Kagansky
Journal:  Front Cell Neurosci       Date:  2018-11-19       Impact factor: 5.505

Review 3.  Role of Senescence in Tumorigenesis and Anticancer Therapy.

Authors:  Ewelina Stoczynska-Fidelus; Marta Węgierska; Amelia Kierasińska; Damian Ciunowicz; Piotr Rieske
Journal:  J Oncol       Date:  2022-03-18       Impact factor: 4.375

4.  Monoallelic IDH1 R132H Mutation Mediates Glioma Cell Response to Anticancer Therapies via Induction of Senescence.

Authors:  Daqian Zhan; Ding Ma; Shuang Wei; Bachchu Lal; Yi Fu; Charles Eberhart; John Laterra; Mingyao Ying; Yunqing Li; Alan Meeker; Hernando Lopez-Bertoni; Shuli Xia
Journal:  Mol Cancer Res       Date:  2021-08-04       Impact factor: 5.852

5.  IDH1R132H in Neural Stem Cells: Differentiation Impaired by Increased Apoptosis.

Authors:  Kamila Rosiak; Maciej Smolarz; Wojciech J Stec; Joanna Peciak; Dawid Grzela; Marta Winiecka-Klimek; Ewelina Stoczynska-Fidelus; Barbara Krynska; Sylwester Piaskowski; Piotr Rieske
Journal:  PLoS One       Date:  2016-05-04       Impact factor: 3.240

6.  Cell line with endogenous EGFRvIII expression is a suitable model for research and drug development purposes.

Authors:  Wojciech J Stec; Kamila Rosiak; Paulina Siejka; Joanna Peciak; Marta Popeda; Mateusz Banaszczyk; Roza Pawlowska; Cezary Treda; Krystyna Hulas-Bigoszewska; Sylwester Piaskowski; Ewelina Stoczynska-Fidelus; Piotr Rieske
Journal:  Oncotarget       Date:  2016-05-31

7.  hTERT Transduction Extends the Lifespan of Primary Pediatric Low-Grade Glioma Cells While Preserving the Biological Response to NGF.

Authors:  Ornella Franzese; Angela M Di Francesco; Daniela Meco; Grazia Graziani; Gabriella Cusano; Lauretta Levati; Riccardo Riccardi; Antonio Ruggiero
Journal:  Pathol Oncol Res       Date:  2021-04-02       Impact factor: 3.201

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.